Former LTT Biopharma VP Charged For Insider Trading
This article was originally published in PharmAsia News
The Japan Stock Exchange Committee charged former LTT Biopharma VP Shigenori Saito for insider trading. According to the charge, in January 2008 while Saito was the president for LTT's subsidiary Asklepios, he became aware of LTT's plan to dissolve the affiliation. In March, Saito knew that the subsidiary company could not repay its debts due to a failed investment, and from March 4 to 19, Saito sold over 11,500 company shares and pocketed ¥412 million in profit. (Click here for more - Japanese language
You may also be interested in...
GlaxoSmithKline’s third quarter results included a 9% decline in sales in its vaccine business, but this was offset by tight cost controls and restructuring benefits; the company expects to continue investing in its pipeline and new product launches.
With many competitor programs on hold during the COVID crisis, L’Oreal dialed up its media investments and launched products over the summer that were postponed from the first quarter, resulting in a return to growth in the firm’s third quarter led by Professional Products and Active Cosmetics.
Just as the MDR and IVDR are being implemented, increasing regulatory divergence in Europe is a growing danger to patient safety throughout the EU. Erik Raadsheer, senior director of Align Technology, expressed concerns.